Abstract
Background:
There is some evidence that systemic inflammation may be associated with survival in patients with prostate cancer; however, it is unclear whether this is independent of grade. We therefore investigated the role of inflammation-based prognostic scores, the modified Glasgow Prognostic Score (mGPS) and neutrophil lymphocyte ratio (NLR), and their associations with Gleason grade in patients with prostate cancer.
Methods:
Patients from a cohort, the Glasgow Inflammation Outcome Study, who had diagnosis of prostate cancer, were included in this study. The mGPS was constructed by combining C-reactive protein and albumin whereas NLR by calculating the ratio of neutrophils to lymphocytes. We estimated 5-year relative survival and relative excess risk (RER) of death by mGPS and NLR categories after adjusting for age, socioeconomic circumstances and Gleason grade.
Results:
In all, 897 prostate cancer patients were identified; of those 422 (47%) died during a maximum follow-up of 6.2 years. Systemic inflammation appeared to have significant prognostic value. The mGPS predicted poorer 5-year overall and relative survival independent of age, socioeconomic circumstances, disease grade and NLR. Raised mGPS also had a significant association with excess risk of death (mGPS 2: RER =2.41, 95% confidence interval 1.37–4.23) among aggressive, clinically significant prostate cancer (Gleason grades 8–10).
Conclusions:
The mGPS is a strong measure of systemic inflammation, when compared with NLR. Prostate cancer patients with a raised mGPS had significantly higher risk of death for overall as well high-grade disease. Inflammation-based prognostic scores predict outcome in patients with prostate cancer and should be added to their routine clinical assessment.
Similar content being viewed by others
References
Ferlay J, Parkin DM, Steliarova-Foucher E . Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765–781.
Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D et al. Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol 2008; 9: 445–452.
Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A . Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010; 46: 3040–3052.
Castelli T, Cimino S, Magno C, Morgia G . Molecular markers for prostatic cancer. Front Biosci 2010; 2: 641–656.
Huang HC, Zheng S, VanBuren V, Zhao Z . Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat 2010; 9: 219–230.
Verhagen PC, Tilanus MG, de Weger RA, van Moorselaar RJ, van den Tweel JG, Boon TA . Prognostic factors in localised prostate cancer with emphasis on the application of molecular techniques. Eur Urol 2002; 41: 363–371.
Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539–545.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A . Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073–1081.
Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
Vasto S, Carruba G, Candore G, Italiano E, Di BD, Caruso C . Inflammation and prostate cancer. Future Oncol 2008; 4: 637–645.
Roxburgh CS, McMillan DC . Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6: 149–163.
McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC . Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006; 77: 127–129.
McArdle PA, Qayyum T, McMillan DC . Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up. Urol Int 2010; 84: 430–435.
Proctor MJ, Talwar D, Balmar SM, O′Reilly DS, Foulis AK, Horgan PG et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer 2010; 103: 870–876.
Sogani PC, Israel A, Lieberman PH, Lesser ML, Whitmore Jr WF . Gleason grading of prostate cancer: a predictor of survival. Urology 1985; 25: 223–227.
Aliustaoglu M, Bilici A, Seker M, Dane F, Gocun M, Konya V et al. The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepato-Gastroenterology 2010; 57: 640–645.
Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JPA et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008; 32: 1757–1762.
Scottish Government. Scottish Index of Multiple Deprivation http://www.scotland.gov.uk/topics/statistics/SIMD. Scottish Government: Scotland, 2006; 1–24.
Proctor MJ, Morrison DS, Talwar D, Balmer SM, O′Reilly DS, Foulis AK et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011; 104: 726–734.
Dickman PW, Coviello E, Hills M . Estimating and modelling relative survival. Stata J 2008; VV: 1–24.
Esteve J, Behamou M, Croasdale M, Raymond L . Relative survival and estimation of net survival: elements for further discussion. Stat Med 1990; 9: 529–538.
Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O′Reilly DS et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; e-pub ahead of print 1 July 2011.
Kaptoge S, Di AE, Lowe G, Pepys MB, Thompson SG, Collins R et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132–140.
Wensley F, Gao P, Burgess S, Kaptoge S, Di AE, Shah T et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. Br Med J 2011; 342: d548.
Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009; 27: 3437–3444.
Acknowledgements
All authors are paid by their employers.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Shafique, K., Proctor, M., McMillan, D. et al. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis 15, 195–201 (2012). https://doi.org/10.1038/pcan.2011.60
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2011.60
- Springer Nature Limited
Keywords
This article is cited by
-
Rat prostate tumors induce DNA synthesis in remote organs
Scientific Reports (2022)
-
Study protocol: a lifestyle intervention for African American and Hispanic prostate cancer survivors on active surveillance and their partners
Pilot and Feasibility Studies (2020)
-
Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR) Versus Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) as Predictors of Outcome in Necrotising Fasciitis
Indian Journal of Surgery (2020)
-
Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients
Scientific Reports (2018)
-
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review
Journal of Inflammation (2016)